Outsourcing Peptide Scale-Up from Milligrams to Kilograms

Moving a peptide from small lab batches to kilogram-scale production is a major milestone. It is also one of the trickiest parts of bringing a peptide drug to market.

Most peptide companies do not have the equipment or expertise to make this jump on their own. That is where contract development and manufacturing organizations, or CDMOs, come in.

Why Scale-Up Is So Challenging for Peptides

Making a few milligrams of a peptide in the lab is very different from making kilograms of the same peptide in a manufacturing plant. Problems that are invisible at small scale can become deal-breakers at large scale.

Coupling reactions that work perfectly at milligram scale may not work as well when the batch size goes up. Side reactions, incomplete couplings, and purification problems all get worse as the scale increases.

A typical 40-amino-acid peptide requires about 80 individual chemical reactions to build. If each reaction works at 99% efficiency, the overall yield at the end is only about 45%. At 98% efficiency, it drops to just 20%.

The Scale-Up Pathway

Peptide scale-up usually follows a step-by-step path from discovery to commercial production. Each step involves larger batches and stricter quality requirements.

Stage	Typical Scale	Purpose	Quality Standard
Discovery	1 to 100 mg	Identify lead peptide	Research grade
Preclinical	100 mg to 10 g	Animal testing and formulation	Non-GMP
Phase I clinical	10 g to 100 g	First human trials	GMP
Phase II clinical	100 g to 1 kg	Larger human trials	GMP
Phase III clinical	1 kg to 10 kg	Pivotal trials	GMP
Commercial	10 kg to 100+ kg	Market supply	GMP

Each step up in scale requires process changes, new equipment, and additional quality controls. What works at one scale may not work at the next.

Why Outsource Scale-Up?

Building the capability to manufacture peptides at kilogram scale in-house requires enormous capital investment. A GMP peptide manufacturing facility can cost $50 million to $100 million or more to build and equip.

CDMOs spread this cost across many clients, which makes outsourcing far more economical for most companies. You pay for what you need when you need it, rather than investing tens of millions in facilities you may not fully use.

CDMOs also bring experience. A good CDMO has scaled up dozens or even hundreds of different peptides and has seen every problem that can arise. This experience is invaluable for avoiding costly mistakes.

Expert Quote: "Scale-up is where good peptide chemistry meets real-world engineering. The CDMO that has done it a hundred times will get it right much faster than a company trying it for the first time.", Dr. Robert Kline, Peptide Manufacturing Consultant

How to Choose a CDMO for Peptide Scale-Up

Picking the right CDMO partner is one of the most important decisions in your drug development program. The wrong choice can set you back months or years.

Key Selection Criteria

Factor	What to Look For
Peptide-specific expertise	Years of experience, number of peptides scaled
Equipment and capacity	Large-scale synthesizers, prep HPLC, lyophilizers
GMP certification	Current certifications from FDA, EMA, or equivalent
Regulatory track record	History of successful regulatory inspections
Analytical capabilities	In-house testing for purity, identity, and stability
Project management	Dedicated project manager, clear communication
Flexibility	Ability to handle schedule changes and scope adjustments
Location	Proximity for visits, regulatory considerations

Visit the CDMO's facility before signing a contract. Meet the team that will work on your project, tour the manufacturing suites, and review their quality systems.

Ask for references from past clients. A good CDMO will be happy to connect you with companies they have worked with before.

The Scale-Up Process Step by Step

A typical peptide scale-up project follows a structured process that takes the peptide from lab scale to manufacturing scale in stages.

Step 1: Technology Transfer

The first step is transferring your peptide synthesis process from your lab to the CDMO. This includes sharing your synthesis protocol, analytical methods, and any special handling requirements.

The CDMO will review your process and may suggest changes to make it more suitable for large-scale production. This is a collaborative step that requires good communication between both teams.

Step 2: Process Development

The CDMO will run small-scale experiments to optimize the synthesis process for their equipment. They may test different resins, solvents, coupling agents, and reaction conditions.

The goal is to find a process that gives high yield and purity while being robust and reproducible. This step usually takes 2 to 4 months and may require several rounds of optimization.

Step 3: Pilot Batches

Once the process is optimized, the CDMO runs one or more pilot batches at an intermediate scale. These batches test whether the process works at a larger scale than the lab but smaller than full production.

Pilot batches also produce material for stability studies, formulation development, and other testing that needs larger amounts of peptide.

Step 4: GMP Manufacturing

If the pilot batches look good, the CDMO moves to GMP manufacturing. This is the final scale-up step, where peptides are made under strict quality controls that meet regulatory requirements.

GMP batches require extensive documentation, in-process testing, and final release testing. Every step is recorded and reviewed by quality assurance before the peptide can be shipped.

Step 5: Ongoing Supply

After the initial GMP batches, the CDMO provides ongoing supply for clinical trials or commercial use. This requires careful planning to make sure material is always available when needed. For additional context, the FDA guidance on contract manufacturing offers relevant guidance on this topic.

For help managing your outsourcing relationships, our guide to CRO partnership management has practical tips.

Common Scale-Up Challenges

Several challenges come up repeatedly during peptide scale-up. Knowing about them in advance helps you plan for and avoid them.

Aggregation. Some peptides tend to clump together at high concentrations. This can clog equipment, reduce yield, and create impurities that are hard to remove.

Difficult sequences. Certain amino acid sequences are notoriously hard to synthesize at scale. Beta-sheet-forming sequences, poly-arginine stretches, and sequences with many hydrophobic residues all cause problems.

Purification bottlenecks. Crude peptide from the synthesis step needs to be purified, usually by preparative HPLC. This step is often the bottleneck because it is slow and uses large amounts of solvent.

Racemization. Some amino acids can flip their configuration during synthesis, creating impurities that are hard to detect and remove. This problem gets worse at larger scales and with longer reaction times.

Purification typically accounts for 40% to 60% of the total cost of large-scale peptide manufacturing. Improving purification efficiency is one of the best ways to reduce costs.

Cost Factors in Peptide Scale-Up

Peptide manufacturing costs depend on many factors. Understanding these factors helps you budget accurately and negotiate better with CDMOs.

Cost Factor	Impact on Price
Peptide length	Longer peptides cost more per gram
Sequence difficulty	Hard sequences require more optimization
Purity requirement	Higher purity means more purification
Scale of production	Larger batches have lower cost per gram
GMP vs. non-GMP	GMP adds 2x to 5x to the cost
Number of batches	More batches spread fixed costs
Special modifications	PEGylation, cyclization, etc. add cost

As a rough guide, GMP peptide manufacturing at kilogram scale typically costs $5,000 to $50,000 per gram, depending on the peptide and the requirements. Simpler peptides at larger scales can be much cheaper.

Expert Quote: "Do not focus only on the cost per gram. Focus on the total cost of getting the right amount of the right quality peptide on time. A cheap CDMO that delivers late or off-spec will cost you far more in the end.", Sarah Mitchell, Peptide Supply Chain Manager

New Technologies Improving Scale-Up

Several new technologies are making peptide scale-up easier and more cost-effective. These innovations are changing the economics of peptide manufacturing.

Continuous flow synthesis replaces the traditional batch process with a continuous stream. This can improve yield, reduce waste, and speed up production.

Green chemistry approaches use less hazardous solvents and produce less waste. This is both environmentally responsible and cost-saving, since solvent purchase and disposal are major expenses.

Automated purification systems can handle larger volumes and make smarter decisions about which fractions to collect. This improves purity while reducing solvent use and labor.

Enzymatic ligation uses enzymes to join peptide fragments together. This can be faster and cleaner than traditional chemical methods for making long peptides.

Regulatory Considerations

GMP peptide manufacturing is heavily regulated. Your CDMO must follow the rules set by the FDA, EMA, and other authorities in your target markets.

Make sure your CDMO has been inspected recently by the relevant regulatory authorities. Ask to see their most recent inspection reports and any findings that were noted.

Your regulatory team should review the CDMO's documentation practices before manufacturing begins. Good documentation is essential for a successful regulatory filing and for defending your manufacturing process during inspections.

For a broader view of peptide regulatory requirements, check out our overview of peptide compliance essentials.

Timeline Planning

Peptide scale-up takes longer than most people expect. Plan your timeline carefully and build in buffers for unexpected delays.

Phase	Typical Duration
CDMO selection and contracting	2 to 4 months
Technology transfer	1 to 2 months
Process development	2 to 4 months
Pilot batches	2 to 3 months
GMP manufacturing (first batch)	2 to 4 months
Release testing and shipping	1 to 2 months
Total	10 to 19 months

Start your CDMO search at least 18 to 24 months before you need your first GMP batch. Good CDMOs fill up their schedules well in advance, and waiting too long to start can push your entire development timeline back.

Frequently Asked Questions

How long does it take to scale up a peptide from milligrams to kilograms?

The entire process typically takes 12 to 24 months, including CDMO selection, process development, pilot batches, and GMP manufacturing. Simpler peptides may be faster, while complex ones may take longer.

How much does peptide scale-up cost?

Costs vary widely based on the peptide's length, complexity, purity requirements, and scale. A full scale-up program from process development through GMP manufacturing can cost $500,000 to $5 million or more depending on the scope.

Can any CDMO handle peptide scale-up?

No. Peptide manufacturing requires specialized equipment and expertise that not all CDMOs have. Look for CDMOs with proven experience in peptide synthesis, purification, and GMP manufacturing specifically.

What is the biggest risk in peptide scale-up?

The biggest risk is discovering that your synthesis process does not work at larger scale after you have already invested significant time and money. This is why thorough process development and pilot batches are so important.

Should I use one CDMO or split work between several?

Using one CDMO simplifies project management and communication. However, some companies use a second CDMO as a backup to reduce supply chain risk. The right approach depends on your specific situation and risk tolerance.